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The figure legend to Figure 2A contained incorrectly calculated SEM values given for disability scores (underlined below). Recalcu-
lated SEM values are now given in brackets below. This correction has, however, no impact on statistical analysis and the findings
reported in this figure.
We apologize to the readers of Neuron for any inconvenience this mistake may have caused.
Figure 2. Immunomodulatory Effect and Systemic Distribution of Intracisternal DR5:Fc
(A) T cells and macrophages/microglia cells were isolated from the brain at the onset of the disease (day 7) (mean disability
score ± SEM for DR5:Fc-treated group 2.63 ± 1.31 (correct SEM: 0.47); for Fc-treated control group 0.75 ± 0.38 (correct SEM:
0.32); n = 4 for both groups) and at the time of remission (day 14) (mean disability score ± SEM at the disease peak for DR5:Fc-treated
group 1.95 ± 0.81 [n = 5]; for Fc-treated control group 2.92 ± 0.60 [n = 6]). Activation markers determined by FACS analysis are given
asmeans with SEM (open bars, treatment with Fc fragment only; filled bars, treatment with DR5:Fc; *p < 0.05, Mann-Whitney U-test).Neuron 75, 541–542, August 9, 2012 ª2012 Elsevier Inc. 541
